Go Pro
NASDAQ:BIOA

BioAge Labs Q4 2025 Earnings Report

BioAge Labs logo
$7.05 0.00 (0.00%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$7.28 +0.23 (+3.26%)
As of 09/25/2026 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioAge Labs EPS Results

Actual EPS
-$0.72
Consensus EPS
-$0.83
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

BioAge Labs Revenue Results

Actual Revenue
$3.08 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioAge Labs Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

BioAge Labs Earnings Headlines

Bioage Labs Inc (BIOA)
BioAge Labs to Present at Upcoming Investor Conferences
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
Financial Comparison: BioAge Labs (BIOA) versus Its Competitors
See More BioAge Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioAge Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioAge Labs and other key companies, straight to your email.

About BioAge Labs

BioAge Labs (NASDAQ:BIOA) (NASDAQ:BIOA) is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. Its research uses human longevity data and proprietary computational biology tools to identify pathways associated with aging-related diseases and to develop potential therapies aimed at extending healthy lifespan and improving physical function.

The company’s lead investigational program is azelaprag, also known as BGE-105, an oral small-molecule apelin receptor agonist being studied for its potential to preserve muscle mass and improve physical performance in older adults. BioAge is also evaluating its broader pipeline in areas such as obesity, metabolic disease, muscle health and immune function, although its programs remain in clinical development and have not been approved for commercial use.

BioAge was founded in 2015 and is headquartered in Richmond, California. The company’s operations are centered on research, drug discovery and clinical development, with studies conducted in collaboration with clinical and research organizations. Kristen Fortney, Ph.D., is the company’s co-founder, president and chief executive officer.

View BioAge Labs Profile